- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Ambrisentan, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 5,558
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Arrhythmia
- Interventions
- office setting, hosptial setting
- Other
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 27
- States / cities
- La Jolla, California • Mission Viejo, California • Sacramento, California + 24 more
- Conditions
- Hypercholesterolemia
- Interventions
- Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
- Conditions
- Huntington's Disease
- Interventions
- coenzyme Q10, placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 37 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- nelarabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 91
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
- Conditions
- Healthy
- Interventions
- 9-day detoxification cleanse and 1 week of pre-cleanse transition
- Dietary Supplement
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
- Device · Drug
- Lead sponsor
- NovoCure GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Fullerton, California + 34 more
- Conditions
- Scarring
- Interventions
- 2-Octyl cyanoacrylate
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Mandibular Fractures
- Interventions
- OmniMax MMF system
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Sacramento, California • Iowa City, Iowa • Charleston, South Carolina
- Conditions
- Gliosarcoma, MGMT-Unmethylated Glioblastoma
- Interventions
- Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
- Procedure · Biological · Device + 3 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 285
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more
- Conditions
- Hemophilia B
- Interventions
- rFIXFc, FIX
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 4 more
- Conditions
- Coronavirus, Acute Respiratory Infection, SARS-CoV Infection
- Interventions
- Hydroxychloroquine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fresno, California • Los Angeles, California + 31 more
- Conditions
- Brain Metastasis, Non-small Cell Lung Cancer
- Interventions
- Patupilone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 12
- States / cities
- Sacramento, California • Boston, Massachusetts • Detroit, Michigan + 7 more
- Conditions
- Meningococcal Meningitis
- Interventions
- MenACWY-CRM conjugate vaccine, Licensed comparator
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Fremont, California • Fresno, California + 21 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
- Interventions
- Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1405
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
- Conditions
- Fibromyalgia
- Interventions
- AXS-14 (esreboxetine)
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Anaheim, California • Oceanside, California + 32 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
- Drug · Procedure
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more
- Conditions
- Brain Diseases, Spinal Cord Diseases
- Interventions
- Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 20
- States / cities
- Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more
- Conditions
- Adult Meningioma
- Interventions
- hydroxyurea
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2011
- U.S. locations
- 133
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 97 more
- Conditions
- Unsedated Colonoscopy, Water Exchange Colonoscopy, Cap, Colonoscopy Pain
- Interventions
- Control, Study method
- Other · Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Sacramento, California • Sepulveda, California
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- Interventions
- HU6, Placebo
- Drug · Other
- Lead sponsor
- Rivus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Chula Vista, California • Los Angeles, California • Montclair, California + 13 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 652
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more